Status:
WITHDRAWN
Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen Treatments
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
Winthrop University Hospital
Conditions:
Spinal Muscular Atrophy
Eligibility:
All Genders
5-21 years
Phase:
EARLY_PHASE1
Brief Summary
It is well known that patients with spinal muscular atrophy (SMA) have progressive decline of respiratory muscle function. Therapy traditionally involved supportive means to ensure optimal nutrition a...
Eligibility Criteria
Inclusion
- Patients diagnosed with SMA of any type who are eligible to start nusinersen treatments at NYU Winthrop Hospital.
Exclusion
- Patients unable to comply with nusinersen treatments according to recommended schedule (first 3 doses every 2 weeks, then the 4th dose is administered 1 month after the 3rd dose, and then maintenance dose administered every 4 months).
Key Trial Info
Start Date :
July 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04050852
Start Date
July 17 2019
End Date
April 1 2021
Last Update
June 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health
New York, New York, United States, 10016